We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Merck & Co. Inc (MRK) is a leading drug manufacturers-general business with stocks listed in the US. It opened the day at US$81.6 after a previous close of US$81.32. During the day the price has varied from a low of USD80.765 to a high of USD81.8521. The latest price was USD81.38 (25 minute delay). Merck-and-CoInc is listed on the NYSE. All prices are listed in US Dollars.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Long-term investing
| Open | US$81.6 |
|---|---|
| High | US$81.8521 |
| Low | US$80.765 |
| Close | US$81.38 |
| Previous close | US$81.32 |
| Change | US$0.06 |
| Change % | 0.0738% |
| Volume | 9,478,020 |
| 52-week range | US$65.9822 - US$90.541 |
|---|---|
| 50-day moving average | US$78.2658 |
| 200-day moving average | US$77.0517 |
| Target price | US$92.5 |
| PE ratio | 28.2216 |
| Dividend yield | US$2.56 (3.45%) |
| Earnings per share (TTM) | US$2.834 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $81.38
| 1 week (2022-01-21) | 1.75% |
|---|---|
| 1 month (2021-12-27) | 6.28% |
| 3 months (2021-10-28) | -5.97% |
| 6 months (2021-07-28) | 3.89% |
| 1 year (2021-01-28) | 9.45% |
|---|---|
| 2 years (2020-01-28) | -1.04% |
| 3 years (2019-01-28) | 17.05% |
| 5 years (2017-01-27) | 38.22% |
Valuing Merck-and-CoInc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Merck-and-CoInc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Merck-and-CoInc's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 28x. In other words, Merck-and-CoInc shares trade at around 28x recent earnings.
That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).
Merck-and-CoInc's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.315. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Merck-and-CoInc's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Merck-and-CoInc's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$21.1 billion (£15.7 billion).
The EBITDA is a measure of a Merck-and-CoInc's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | US$52.6 billion |
|---|---|
| Operating margin TTM | 33.82% |
| Gross profit TTM | US$34.6 billion |
| Return on assets TTM | 12.13% |
| Return on equity TTM | 26.04% |
| Profit margin | 13.68% |
| Book value | 14.174 |
| Market capitalisation | US$202 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Merck-and-CoInc.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 28.35
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Merck-and-CoInc's overall score of 28.35 (as at 12/31/2018) is nothing to write home about – landing it in it in the 47th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Merck-and-CoInc is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 3.15/100
Merck-and-CoInc's environmental score of 3.15 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-CoInc is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 15.55/100
Merck-and-CoInc's social score of 15.55 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-CoInc is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 12.65/100
Merck-and-CoInc's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Merck-and-CoInc is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Merck-and-CoInc scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Merck-and-CoInc hasn't always managed to keep its nose clean.
Merck & Co. Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 28.35 |
|---|---|
| Total ESG percentile | 47.16 |
| Environmental score | 3.15 |
| Environmental score percentile | 4 |
| Social score | 15.55 |
| Social score percentile | 4 |
| Governance score | 12.65 |
| Governance score percentile | 4 |
| Level of controversy | 3 |
Dividend payout ratio: 45.15% of net profits
Recently Merck-and-CoInc has paid out, on average, around 45.15% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.45% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Merck-and-CoInc shareholders could enjoy a 3.45% return on their shares, in the form of dividend payments. In Merck-and-CoInc's case, that would currently equate to about $2.56 per share.
While Merck-and-CoInc's payout ratio might seem fairly standard, it's worth remembering that Merck-and-CoInc may be investing much of the rest of its net profits in future growth.
Merck-and-CoInc's most recent dividend payout was on 6 January 2022. The latest dividend was paid out to all shareholders who bought their shares by 13 December 2021 (the "ex-dividend date").
Merck-and-CoInc's shares were split on a 1048:1000 basis on 2 June 2021. So if you had owned 1000 shares the day before the split, the next day you would own 1048 shares. This wouldn't directly have changed the overall worth of your Merck-and-CoInc shares – just the quantity. However, indirectly, the new 4.6% lower share price could have impacted the market appetite for Merck-and-CoInc shares which in turn could have impacted Merck-and-CoInc's share price.
Over the last 12 months, Merck-and-CoInc's shares have ranged in value from as little as US$65.9822 up to US$90.541. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Merck-and-CoInc's is 0.4952. This would suggest that Merck-and-CoInc's shares are less volatile than average (for this exchange).
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Synthekine Inc.; and Ridgeback Biotherapeutics. It also has collaboration agreements with Hummingbird Bioscience Pte. Ltd; Gilead Sciences, Inc. to co-develop and co-commercialize investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; Linnaeus Therapeutics, Inc. to evaluate LNS8801; Biomed X Gmbh for building on ongoing research projects in the fields of oncology and autoimmunity; NGM Biopharmaceuticals, Inc. to focus on the development of medicines in retinal and CVM diseases, as well as to develop and commercialize tests that identify genetic mutations; and IO Biotech ApS to evaluate IO102-IO103. It also has a partnership with Biocorp Production for the development and supply of Mallya device; and a licensing agreement with The Medicines Patent Pool to facilitate access for molnupiravir, an investigational oral COVID-19 antiviral medicine. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
In an exclusive interview with Finder, VP of Strategic Innovations Lab, Nicolas Pouard, spells out he future of Ubisoft's NFTs
BMW Australia's 8 Series range is set to receive an update for 2022 with slightly refreshed styling and additional tech headlining its flagship luxury sports model.
The current market sell-off is providing an opportunity for investors to pick up structural winners at a discount, two industry experts say.
Recovering from trauma is a lengthy process.
We talk to Nicolas Pouard, VP at Ubisoft's Strategic Innovations Lab, about the launch of Ubisoft Quartz and the Digits NFTs
Find out why and how much it's likely to cost you.
On your marks, get set, bake!
Hotel quarantine could cost you thousands unless you get the right travel insurance policy.
Your credit limits can affect your credit score and your chance of approval, but it's not always as simple as changing one to improve the other.
